Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Johnson & Johnson Settles Talc Baby Powder Lawsuit in January 2025

January 02, 2025
Johnson & Johnson (JNJ) has recently reached a settlement in the longstanding talc powder ovarian cancer lawsuit. The settlement, which was reached in January 2025, puts an end to a legal battle that has been ongoing for several years. While the details of the settlement remain confidential, it is a significant development for both the company and the plaintiffs.

The talc powder ovarian cancer lawsuit alleged that Johnson & Johnson's talcum powder products caused ovarian cancer in women who used them for personal hygiene. The company has consistently denied these allegations and maintained that its products are safe. However, the lawsuit has led to several significant legal victories for the plaintiffs in the past.

Despite the settlement, Johnson & Johnson's stock, traded under the ticker symbol JNJ, has been performing exceptionally well. While the broader market has experienced fluctuations and declines, JNJ has been consistently ascending. This is attributed to the company's diversified portfolio of products, including pharmaceuticals, medical devices, and consumer health products.

Investors have been closely watching the company's talcum powder litigation, as it has the potential to impact Johnson & Johnson's reputation and financial performance. While the settlement is a positive development, some investors are still waiting for a pullback in the stock before making any significant investment decisions.

For those interested in the future movement of Johnson & Johnson's stock, experts recommend seeking guidance from professionals in Stocks Prognosis. Their expertise and analysis can provide valuable insights into the company's prospects and help investors make informed decisions. With Johnson & Johnson's talcum powder litigation behind it, the company can now focus on its core businesses and continue delivering innovative products for its customers.
If you want to leave a comment, then you need Login or Register





Other data for JNJ

Related data

JNJJuly 14, 2025Johnson & Johnson Innovates with New Product Launches  ~1 min.

Johnson & Johnson, a leading pharmaceutical company, continues to make waves in the industry with its latest submission of sNDA for the schizophrenia drug CAPLYTA to the FDA....

JNJMay 25, 2025Revolutionary Innovation: JNJ Johnson & Johnson Leads the Medical Industry with Groundbreaking Technology  ~1 min.

Johnson & Johnson, the renowned medical technology company, continues to be at the forefront of innovation in the industry....

JNJMarch 21, 2025Johnson & Johnson Neurovascular leader heads for the exit  ~1 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, has announced his departure from the company....

JNJMarch 20, 2025Johnson & Johnson Faces Shareholder Activism Over Human Rights and Executive Pay Proposals  ~2 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, is leaving the company, according to sources....

JNJMarch 19, 2025FDA Clears Johnson & Johnson Robot for Enhanced Bronchoscopy  ~1 min.

Johnson & Johnson's MedTech division has received clearance from the FDA for its enhanced robotic-assisted bronchoscopy system....

JNJMarch 18, 2025Johnson & Johnson MedTech Introduces New EP Neurovascular Leader  ~1 min.

Johnson & Johnson MedTech, a subsidiary of Johnson & Johnson, has appointed a new leader for its electrophysiology and neurovascular group....

JNJMarch 14, 2025Johnson & Johnson's Decades-Long Quest for Effective IBD Treatments  ~1 min.

Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....

JNJFebruary 28, 2025Johnson & Johnson's Strong Performance Since Last Earnings Report Raises Expectations  ~1 min.

Johnson & Johnson (JNJ) has shown an impressive 8.9% increase in its stock price since the release of its last earnings report....

JNJFebruary 26, 2025The surgical devices I design for JJ speed healing and save lives  ~1 min.

Johnson & Johnson (JNJ) has been at the forefront of medical technology, constantly innovating and developing breakthrough surgical devices that not only speed up the healing process but also save lives....

JNJFebruary 18, 2025Johnson & Johnson reportedly wants to sell Cerenovus for 1B  ~1 min.

According to recent reports, Johnson & Johnson is considering selling its Cerenovus stroke business for 1 billion dollars....

JNJJanuary 2, 2025Talc Baby Powder Lawsuit: January 2025 Settlement Update  ~2 min.

Recent updates on the ongoing Talc Baby Powder Lawsuit against Johnson & Johnson (JNJ) reveal progress towards a possible settlement....

GSKMarch 21, 2025GSK Lead Plaintiff Deadline Approaching - Contact Robbins LLP for Information About How to Lead the GSK PLC Class Action  ~2 min.

GSK PLC, a global pharmaceutical company, is facing a class action lawsuit....

ABBVJanuary 2, 2025AbbVie Inc. ABBV - A Promising Pharma Dividend Stock to Consider  ~2 min.

Pharmaceutical giant AbbVie Inc. (NYSE: ABBV) has been capturing the attention of investors with its impressive performance and consistent dividend payouts....

AZNFebruary 2, 2025Shareholders of AstraZeneca PLC Should Contact Levi Korsinsky Before February 21 2025 to Discuss Your Rights  ~2 min.

It has come to light that shareholders of AstraZeneca PLC (AZN) are urged to contact Levi Korsinsky, a renowned law firm specializing in securities litigation, before February 21, 2025, to discuss their rights. AstraZeneca PLC, a global pharmaceutical company, has been facing potential legal implications due to recent developments in the industry. Levi Korsinsky is currently investigating possible...

REGNFebruary 2, 2025Regeneron Pharmaceuticals Inc. Faces Class Action Lawsuit  ~2 min.

Regeneron Pharmaceuticals Inc. (REGN) is currently facing a class action lawsuit filed by investors....